Abstract
This report presents the results of third-party analytical testing conducted on a single vial of Olympic Peptides KLOW 80 mg (Lot OLYP8245) by Freedom Diagnostics Testing (Accession #2602020389). The vial was reconstituted with standard bacteriostatic water and sampled at four time points over approximately 30 days. Peptide content was measured by reversed-phase high-performance liquid chromatography with ultraviolet detection (RP-HPLC-UV) and confirmed by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Across all four measurements, composite blend purity ranged from 99.49% to 99.62% (mean 99.56% ± 0.06%). Observed variations in individual peptide content across time points were small in magnitude and non-directional for three of the four analytes, consistent with measurement variability inherent to the analytical method rather than systematic chemical degradation. These findings indicate that no measurable degradation was detected under the conditions tested; however, the single-vial, single-lot design of this assessment precludes formal statistical inference, and the results should be interpreted as preliminary observational data. Further controlled stability studies with appropriate replication would be required to establish validated stability specifications.
1. Background: The Social Media Debate
Over the past twelve months, a significant debate has emerged on platforms including YouTube, Instagram, and TikTok concerning the compatibility and stability of multi-peptide blends. These blends — marketed under names such as “GLOW” and “KLOW” — combine GHK-Cu (copper peptide), BPC-157 (Body Protection Compound-157), Thymosin Beta-4 (TB-500 fragment), and KPV (a tripeptide of α-MSH) into a single reconstituted vial for subcutaneous or topical administration.
Critics, including several prominent online commentators, have asserted the following claims:
Claim 1 — pH Incompatibility: That the different isoelectric points (pI) and optimal pH ranges of these peptides are mutually incompatible when co-formulated, leading to precipitation, conformational changes, or immediate degradation upon mixing.
Claim 2 — Copper-Catalyzed Oxidation: That the copper ion bound in GHK-Cu catalyzes oxidative degradation of adjacent peptides (particularly those containing methionine, cysteine, or other redox-active residues), rendering co-mixed preparations chemically compromised.
Claim 3 — Rapid Potency Loss: That reconstituted multi-peptide vials lose a substantial fraction of potency within days to weeks, with one source citing losses exceeding 60% (Ninjathlete, 2025; no primary data or citations provided).
These claims have generated considerable uncertainty among consumers and researchers, leading to confusion about the utility and safety of pre-blended peptide formulations.
2. Study Objective
To evaluate whether measurable degradation of any individual peptide component is detectable in a single vial of Olympic Peptides KLOW 80 mg following reconstitution with bacteriostatic water and refrigerated storage over approximately 30 days, using validated third-party analytical methods.
3. Materials & Methods
3.1 Test Article
3.2 Testing Laboratory
3.3 Analytical Methods
3.4 Sampling Design
The reconstituted vial was sampled on four separate occasions over approximately 30 days (Sample 1 near reconstitution, Samples 2–4 at progressive intervals). Exact inter-sample intervals are not specified in the Certificate of Analysis; the sampling represents a real-world usage scenario rather than a formal time-point-controlled stability protocol. Each measurement was performed on the same vial; no independent replicate vials or freshly reconstituted controls were analyzed in parallel at each time point.
This assessment is based on four measurements from a single vial of a single lot. It does not constitute a formal ICH-compliant stability study and should not be interpreted as establishing a validated shelf life or expiry specification. Findings are observational and hypothesis-generating.
4. Results
4.1 Composite Blend Purity
Purity of the reconstituted blend, measured as the percentage of the total HPLC chromatogram represented by the four target peptide peaks, was highly consistent across all four samples:
Mean purity: 99.56% ± 0.06% (SD) | Range: 99.49% – 99.62% | Total spread: 0.13 percentage points
The purity range observed (0.13 pp) is well within the typical day-to-day precision of RP-HPLC methods, which generally carry a coefficient of variation of 0.5–2.0% for complex matrices.
4.2 Individual Peptide Content Over Time
| Peptide | Sample 1 (mg) | Sample 2 (mg) | Sample 3 (mg) | Sample 4 (mg) | Δ (S4 – S1, mg) | Δ (%) | Trend |
|---|---|---|---|---|---|---|---|
| GHK-Cu | 58.39 | 58.11 | 58.01 | 57.91 | −0.48 | −0.82% | Monotonically decreasing |
| KPV | 8.78 | 8.66 | 8.71 | 8.73 | −0.05 | −0.57% | Non-monotonic (dip then recovery) |
| BPC-157 | 11.02 | 10.71 | 10.99 | 10.82 | −0.20 | −1.82% | Non-monotonic (oscillating) |
| Thymosin Beta-4 | 11.51 | 11.34 | 11.12 | 11.26 | −0.25 | −2.17% | Non-monotonic (recovery at S4) |
Note: “Monotonically decreasing” for GHK-Cu describes the observed numeric pattern across four data points; it does not constitute evidence of true chemical degradation in the absence of statistical testing. “Non-monotonic” patterns for KPV, BPC-157, and Thymosin Beta-4 (i.e., values that decrease then increase, or oscillate) are inconsistent with progressive degradation and are more characteristic of random analytical measurement variation.
5. Descriptive Statistical Summary
In the absence of replicate vials or a formal control arm, traditional inferential statistical tests (e.g., paired t-test, regression analysis for trend) cannot be meaningfully applied to declare statistical significance. The following descriptive statistics characterize the variability observed:
| Peptide | Mean (mg) | SD (mg) | %CV | Min (mg) | Max (mg) | Total Δ (%) | Pattern Consistent With Degradation? |
|---|---|---|---|---|---|---|---|
| GHK-Cu | 58.11 | 0.21 | 0.36% | 57.91 | 58.39 | −0.82% | Possible — but within HPLC CV |
| KPV | 8.72 | 0.050 | 0.57% | 8.66 | 8.78 | −0.57% | No — non-monotonic |
| BPC-157 | 10.89 | 0.146 | 1.34% | 10.71 | 11.02 | −1.82% | No — non-monotonic |
| Thymosin Beta-4 | 11.31 | 0.163 | 1.44% | 11.12 | 11.51 | −1.82% | No — non-monotonic |
| Blend Purity Mean | 99.56% | 0.06% | 0.06% | 99.49% | 99.62% | ||
The coefficient of variation (%CV) for all four peptides (0.36% – 1.44%) falls within the typical intra-day precision range of HPLC-UV methods for peptide quantification (generally ≤2–5% for complex matrices). The non-monotonic patterns observed for KPV, BPC-157, and Thymosin Beta-4 — where values fluctuate up and down across time points — are not consistent with a progressive degradation process. Instead, these patterns are more parsimoniously attributed to random analytical measurement error.
For GHK-Cu, the monotonically decreasing pattern across four time points is noteworthy; however, the total magnitude of decrease (0.48 mg over ~30 days, −0.82%) is small relative to the nominal content and does not constitute evidence of clinically meaningful loss. Determination of whether this represents true chemical degradation would require replicated experiments with appropriate controls.
Conclusion from statistics: No statistically significant degradation is observed within the constraints of this single-vial, four-measurement dataset.
6. Interpretation
6.1 On pH and Formulation
The four peptides in the KLOW blend have differing chemical properties. GHK-Cu is a tripeptide-copper chelate with an approximate pI of 5.6; KPV (Lys-Pro-Val) is a neutral tripeptide; BPC-157 is a 15-amino acid synthetic pentadecapeptide; and Thymosin Beta-4 is a 43-amino acid actin-sequestering protein fragment. These peptides span different molecular sizes and charge profiles, which forms the basis of influencer concerns about compatibility.
Bacteriostatic water (USP grade, 0.9% benzyl alcohol) has no buffering capacity and a typical pH range of approximately 4.5–7.0, commonly near 5.5–6.5 when freshly prepared. This pH range is generally tolerated by all four peptides without evidence of immediate precipitation or gross conformational disruption, as confirmed by the physical description in the COA (blue lyophilized powder dissolving normally, no cloudiness noted).
The absence of a specialized buffer does not automatically confer instability. Peptide stability in solution is governed primarily by temperature, light exposure, oxidative environment, and freeze-thaw cycles rather than by pH alone, provided the formulation pH does not approach the extremes where unfolding or charge-mediated aggregation is expected.
6.2 On Copper-Catalyzed Oxidation
The hypothesis that GHK-Cu promotes copper-catalyzed oxidative degradation of co-formulated peptides is chemically plausible under specific conditions: elevated temperature, alkaline pH, the presence of free (unbound) copper ions, and oxygen-rich environments. However, GHK-Cu carries copper in a stably chelated form, and the analysis presented here — conducted under refrigerated conditions — did not reveal any oxidation-consistent degradation signature. This is consistent with the broader literature indicating that copper chelates exhibit substantially reduced redox activity compared to free ionic copper (Cu²⁺) in solution.
Importantly, neither the COA methodology nor this report can directly confirm or exclude small-scale oxidative modification at the molecular level (e.g., methionine sulfoxide formation) without additional peptide mapping by MS/MS fragmentation analysis. The LC-MS/MS confirmation performed here established identity and gross content, not sub-residue oxidation state.
6.3 On the 60% Potency-Loss Claim
The circulating claim that multi-peptide blends lose greater than 60% of their potency rapidly (attributed to Ninjathlete, 2025) is not supported by any published primary data, peer-reviewed study, or formal analytical report known to us. The data presented in this COA — showing content variations of less than 2.2% over 30 days — are inconsistent with losses of that magnitude. While this single dataset cannot rule out such losses under different storage conditions, formulation approaches, or manufacturing processes, the burden of proof for so specific and large a claim lies with those making it.
7. Study Limitations
Single vial, single lot: All four measurements were taken from one vial of one production lot. Results may not generalize across different lots, manufacturing batches, or independent preparations.
No replicate controls: Without freshly reconstituted control vials measured at each time point, it is impossible to distinguish true chemical changes from inter-measurement analytical variance. A formal stability study would include ≥3 replicate vials per time point, multiple time points, and bracketing and matrixing designs per ICH Q1A(R2) guidance.
Exact time points not recorded: The COA does not document the precise dates or intervals of each sampling; therefore, no kinetic degradation rate (e.g., k, t½) can be calculated.
Storage conditions not fully controlled: Temperature was described as refrigerated, but continuous temperature monitoring data were not reported. Transient temperature excursions cannot be excluded.
Molecular-level integrity not fully assessed: HPLC-UV quantifies intact peptide peaks but does not detect subtle oxidative modifications (e.g., methionine sulfoxide) or deamidation events that may alter biological activity without substantially reducing chromatographic peak area. Full characterization would require peptide mapping and MS/MS fragmentation analysis.
Biological activity not assessed: Analytical purity and content are surrogates for potency. Receptor binding assays or cell-based bioassays were not performed and would be required to directly assess functional stability.
Lyophilized product only: These results apply to this specific lyophilized formulation reconstituted as described. DIY preparations mixing separately sourced peptides may behave differently.
8. Contextual Evidence from Independent Sources
The findings of this assessment are broadly consistent with other independent evaluations of similar multi-peptide blends:
| Source | Product Tested | Method | Duration | Key Finding |
|---|---|---|---|---|
| Freedom Diagnostics Testing (this report, 2026) | Olympic Peptides KLOW 80 mg | HPLC-UV + LC-MS/MS | ~30 days | Purity 99.49–99.62%; Δ content <2.2% for all peptides; no monotonic degradation in 3 of 4 analytes |
| Janoshik Analytical (Test #93983) | KLOW 80 mg blend (Xcel Peptides) | HPLC | 21–28 days | No abnormal degradation reported for any component |
| Chris Duffin / Independent (YouTube, 2025) | Commercial GLOW and KLOW blends | Chromatography (method unspecified) | ~30 days | Purity 99.5% before → 99.6% after; described as “zero degradation” |
Convergent results across independently tested samples, laboratories, and products strengthen confidence in the overall finding that commercially manufactured GLOW/KLOW-type blends do not exhibit rapid or substantial peptide degradation under refrigerated storage conditions. Notably, the Janoshik and Duffin assessments involved different product sources and laboratories, reducing the likelihood that these findings are an artifact of a single formulation or analytical approach.
Relevant scholarly literature also supports the general stability of peptides in reconstituted form when properly stored. A 2022 review in Pharmaceutics (MDPI) notes that lyophilized peptide preparations consistently demonstrate greater stability than liquid formulations, and that reconstituted lyophilisates stored at 2–8 °C typically maintain acceptable potency for periods ranging from weeks to months, depending on formulation composition and molecular characteristics.
9. Conclusion
Based on third-party analytical testing by Freedom Diagnostics Testing (Accession #2602020389) using RP-HPLC-UV with LC-MS/MS confirmation, a single vial of Olympic Peptides KLOW 80 mg (Lot OLYP8245), reconstituted with standard bacteriostatic water and stored under refrigeration for approximately 30 days, demonstrated the following:
- Composite blend purity remained consistently high across all four measurements (mean 99.56% ± 0.06%), with a total range of only 0.13 percentage points.
- Individual peptide content variations were small in magnitude (<2.2% total change) and non-directional for three of four analytes (KPV, BPC-157, Thymosin Beta-4), a pattern inconsistent with progressive chemical degradation.
- GHK-Cu showed a monotonically decreasing pattern (−0.82%), which, while consistent with the observed values, falls well within HPLC analytical variability and does not constitute evidence of degradation in the absence of appropriate controls.
- All four peptide identities were confirmed by LC-MS/MS, indicating structural integrity at the level detectable by mass spectrometry.
These findings do not support the claim that co-formulation of GHK-Cu with BPC-157, KPV, and Thymosin Beta-4 results in rapid or substantial peptide degradation under refrigerated conditions. The frequently cited claim of greater-than-60% potency loss is not consistent with the data presented here or with any other published analytical assessment known to us.
Nonetheless, this assessment has important limitations — chiefly, its single-vial, single-lot, uncontrolled design — that preclude definitive stability claims. Olympic Peptides acknowledges these limitations and intends these findings as a preliminary demonstration of product quality, not as a substitute for a formally designed stability program. We are committed to advancing more rigorous stability characterization of our formulations as part of our ongoing quality and science program.
10. Olympic Peptides’ Commitment to Analytical Transparency
At Olympic Peptides, we believe that the research community deserves data — not assertions. The controversy surrounding multi-peptide blends has largely been conducted in the absence of primary analytical evidence, with influential voices on both sides of the debate relying on theoretical arguments rather than direct measurement.
This third-party COA represents our commitment to changing that dynamic. We commission independent analytical testing precisely because we recognize that our own claims carry inherent bias, and that meaningful quality assurance requires external verification. The selection of Freedom Diagnostics Testing — an independent laboratory with no commercial relationship to Olympic Peptides beyond this testing engagement — reflects our commitment to that principle.
We also recognize what this data can and cannot tell us. We are not claiming that the findings presented here represent a definitive or comprehensive stability profile. Rather, they represent one piece of rigorous, reproducible evidence in an otherwise evidence-poor landscape. We encourage researchers, healthcare professionals, and informed consumers to evaluate this data critically, apply it within its stated limitations, and hold all peptide manufacturers to the same standard of analytical transparency.
“The goal of science is not certainty — it is the honest reduction of uncertainty. We offer this data not as proof of everything, but as a step toward the kind of evidence base this field deserves.”
— Olympic Peptides Research Team
Our future commitments include: commissioning replicated, time-point-controlled stability studies across multiple lots; expanding identity and purity testing to include sub-residue oxidation mapping by MS/MS fragmentation; and publishing all COAs on our website for public access and scientific review.
References
- Freedom Diagnostics Testing. Certificate of Analysis, Accession #2602020389. February 4, 2026.
- Janoshik Analytical. Test Report #93983 — KLOW 80 mg Degradation Study (21-day). Available: https://janoshik.com/tests/93983-KLOW_80MG_21day_degr_6CX5YA7PHJ28
- Duffin C. “They Said Mixing Peptides Breaks Them — The Definitive Proof.” YouTube. 2025. https://www.youtube.com/watch?v=6QMBZpeL_rs
- Bachmeyer T. “Can You Mix Peptides Together — Unbreakable Podcast 273.” YouTube. 2025. https://www.youtube.com/watch?v=7vsau7C_oaA
- Holyfield J. “BPC-157 + TB-500 Wolverine Stack: My Results & How It Works.” YouTube. 2025. https://www.youtube.com/watch?v=LuBhP2rUCFc
- Wang W, et al. “Lyophilization of Protein Pharmaceuticals.” Biotechnol Prog. 2000;16(3):341–351.
- Kasper JC, Friess W. “The importance of drying in parenteral nutrition.” Eur J Pharm Biopharm. 2011;78(2):248–263.
- ICH Q1A(R2): Stability Testing of New Drug Substances and Products. International Council for Harmonisation. 2003.
- Fosgerau K, Hoffmann T. “Peptide therapeutics: current status and future directions.” Drug Discov Today. 2015;20(1):122–128.
- Ninjathlete (online blog). “Why GLOW and KLOW Peptide Blends are Dead on Arrival.” 2025. https://ninjathlete.com/blogs/article/why-glow-and-klow-peptide-blends-are-dead-on-arrival [No primary data cited; not peer-reviewed.]